HHS Peptide Policy: Six Peptides, Ten Conditions

The HHS peptide policy says the department does not intend to take enforcement action against certain licensed compounders using six named peptides. All ten conditions must be met. The stated endpoint is a final rule deciding whether each peptide belongs on the federal compounding ingredient list.

Peptides are short chains of protein building blocks. For someone considering BPC-157, this is a new public policy document. It does not approve a medicine or establish that it works.

What the HHS peptide policy actually says

As of October 29, 2026, the day this article was written, HHS has released its policy text and a notice calling it a “draft.” HHS is the Department of Health and Human Services. Its Office of the Secretary issued the notice, signed by Secretary Robert F. Kennedy, Jr. The policy text itself calls it an “interim policy,” and neither document states a date on which it takes effect.

The Federal Register notice carries this stamp: “Filed: 10/28/2026 11:15 am; Publication Date: 10/30/2026.” Publication is scheduled for October 30. The Federal Register is the government's official journal of notices and rules.

OIRA's completed-review record, from the White House office that reviews agency actions, lists receipt on October 14. It records “Consistent with Change” and a concluded date of October 27. The record carries the same RIN as the notice, 0910-ZD94, under the title “Interim Access Policy for Compounding Using Certain Peptides.” Our October filing background follows the earlier review stage.

Enforcement discretion means stating when the department does not intend to take action. HHS says its aim is to expand and improve patient access while FDA reviews these substances, and to discourage widespread use of peptides sold for laboratory use by foreign manufacturers, which it says pose a safety risk to U.S. patients. Here it addresses Section 503A, the federal framework for compounding medicines for individual patients. Compounding means preparing a medicine for a particular prescription.

The six peptides, chemical forms and routes

The HHS policy's Appendices A and B name these substances and limits. Acetate is a salt form, with the peptide paired with acetic acid. Free base means the form without an added salt.

Subcutaneous means under the skin; intramuscular means into muscle. Oral means by mouth, topical means on the skin, and intranasal means in the nose. Intermittent courses means treatment separated by breaks. These are the policy's limits, not a dosing plan.

BPC-157 remains not FDA-approved. The other five are not FDA-approved either. The document addresses enforcement policy; the clinical evidence remains a separate question.

All ten conditions, in plain words

HHS names state-licensed pharmacies, federal facilities and licensed physicians. Its numbered conditions work together; meeting only some does not meet the policy's terms.

1. The list: the peptide must appear in Appendix A.
2. The exact substance: its identity and route must match Appendix B.
3. The testing record: the ingredient must come from a facility registered with FDA under Section 510 of federal drug law. Its valid certificate of analysis must meet Appendix B’s testing criteria.
4. The original manufacturer: it must be registered with FDA under Section 510 and comply with current good manufacturing practice, the standards for making drug ingredients, and other applicable requirements of federal drug law. Its facility’s physical location must appear on the certificate supplied to the compounder. If the ingredient comes through an FDA-registered repacker, relabeler or reseller, that intermediary must itself have performed and documented appropriate validation of the original manufacturer and the manufacturer’s certificate of analysis.
5. Reporting: compounders report compounded products, serious adverse events and product-quality issues to FDA and to the states where the products are compounded and sent, if different. Serious adverse events, whether or not considered drug-related, and product-quality issues go to FDA’s MedWatch program. Product reports identify the active ingredient and its strength per unit, the original manufacturer and its facility’s unique identifier, and the dosage form and route. HHS says the labeling given to the patient should detail how to report problems.
6. The label: it must state, “This is a compounded drug product. Not for resale.”
7. One active ingredient: the preparation contains only a single active pharmaceutical ingredient, the substance intended to produce an effect, listed in Appendix A.
8. Oral preparations: for an oral dosage form, the compounder is expected to keep documentation confirming that the specific formulation provided to a patient achieves adequate oral bioavailability in humans, meaning enough of the drug reaches the bloodstream after swallowing.
9. The delivery device: any device packaged with or containing the drug must be an FDA 510(k)-cleared syringe, a syringe cleared through FDA's device-review process.
10. The other requirements: all other applicable federal drug-law conditions remain, including a valid patient-specific prescription and preparation without insanitary conditions, meaning conditions that could contaminate medicine.

A certificate of analysis is a batch's laboratory report. Appendix B requires checks beyond a purity percentage, including ingredient identity, strength, impurities and contamination. The manufacturer named on that paperwork must be the original producer, rather than merely a distributor.

What this leaves unsettled

HHS states: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.”

The draft is nonbinding and creates no legal rights. HHS says it may revisit the policy, in whole or in part, if, among other things, a safety signal or product-quality issue arises with a compounded drug product within its scope. It also leaves the final 503A bulks list, the list of raw ingredients established by regulation, to future rulemaking.

Appendix B records that FDA's drug-review staff recommended against listing each of the six, while the Pharmacy Compounding Advisory Committee, which met in July, voted in favor. Our account of the committee decision covers that disagreement. The six peptides’ earlier Category 2 classification, FDA’s interim group for substances that raise significant safety risks, ended April 22, 2026; HHS says neither the placement nor the removal changed their status under Section 503A.

A licensed provider may still prescribe — that decision is between you and your doctor.

A policy document does not add clinical trial results

As of October 29, 2026, the day this article was written, an October 8 review in Acta Orthopaedica Belgica adds useful context. Its search through June 1 included three human BPC-157 studies totaling 30 participants. The authors rated the evidence very low certainty, meaning confidence in treatment conclusions was very limited. They concluded that BPC-157 should not be used clinically outside ethically approved trials.

One was the Lee and Burgess pilot in Alternative Therapies in Health and Medicine, 2025. It gave intravenous infusions to two previously exposed adults over three days and reported no side effects. That cannot establish long-term safety.

For MOTS-c, the original Cell Metabolism paper by Lee and colleagues, 2015 studied treatment effects in cells and mice. Mouse results do not establish benefits for patients. The MOTS-c review history and Semax review history follow their separate evidence records.

What this means for a patient

The policy's conditions are written to the pharmacy, federal facility or physician doing the compounding, not to the patient. For a patient, an anonymous vial from a seller and a prescription from a named clinician, filled by a licensed pharmacy, are not the same relationship. Our gray-market peptides guide explains that difference.

Whether peptides are legal is a separate question: the notice says the draft policy “does not establish any rights for any person and is not binding on HHS or the public,” and state requirements also apply.

For a suspected side effect or quality problem, FDA MedWatch accepts reports from patients as well as health professionals. Its online “Report a Problem” link starts the reporting process.

What to watch next

The next dated step is the scheduled October 30 Federal Register publication. The notice invites comments through regulations.gov on docket HHS-OASH-2026-0496 “until 2 weeks after date of publication.” It does not print a calendar closing date.

Further HHS revisions, any separate FDA statement and eventual final ingredient-list rules will each need their own reading. The six-peptide document answers what HHS had put in writing as of October 29, 2026; the notice says HHS's website carries the most current version of the policy. It does not choose a treatment for an individual.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy prepares and dispenses the medication.